Lucid Diagnostics Inc. (NASDAQ:LUCD) Short Interest Up 72.1% in February

Lucid Diagnostics Inc. (NASDAQ:LUCD) was the recipient of a large increase in short interest in February. As of February 28th, there was short interest totalling 1,790,000 shares, an increase of 72.1% from the February 13th total of 1,040,000 shares. Currently, 5.6% of the company’s shares are sold short. Based on an average trading volume of 576,100 shares, the short-interest ratio is currently 3.1 days.

Analyst Upgrades and Downgrades

Separately, Ascendiant Capital Markets decreased their target price on Lucid Diagnostics from $7.25 to $7.00 and set a “buy” rating for the company in a research report on Monday, December 9th. Four analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, Lucid Diagnostics has an average rating of “Buy” and an average target price of $3.63.

Lucid Diagnostics Stock Up 8.6 %

NASDAQ:LUCD traded up $0.11 during midday trading on Friday, hitting $1.39. The company had a trading volume of 1,217,282 shares, compared to its average volume of 339,024. The stock’s fifty day moving average price is $1.14 and its 200-day moving average price is $0.96. The company has a market capitalization of $82.49 million, a PE ratio of -1.22 and a beta of 1.34. Lucid Diagnostics has a 52-week low of $0.63 and a 52-week high of $1.63.

Hedge Funds Weigh In On Lucid Diagnostics

Institutional investors have recently bought and sold shares of the stock. Sargent Investment Group LLC bought a new stake in shares of Lucid Diagnostics during the fourth quarter valued at approximately $442,000. Citadel Advisors LLC purchased a new position in shares of Lucid Diagnostics during the 4th quarter valued at $98,000. Sunbelt Securities Inc. purchased a new position in shares of Lucid Diagnostics during the 4th quarter valued at $67,000. Geode Capital Management LLC increased its holdings in Lucid Diagnostics by 30.9% in the 4th quarter. Geode Capital Management LLC now owns 279,504 shares of the company’s stock valued at $229,000 after acquiring an additional 65,964 shares during the last quarter. Finally, Lido Advisors LLC increased its holdings in Lucid Diagnostics by 40.0% in the 4th quarter. Lido Advisors LLC now owns 140,016 shares of the company’s stock valued at $115,000 after acquiring an additional 40,000 shares during the last quarter. 74.01% of the stock is owned by institutional investors.

About Lucid Diagnostics

Lucid Diagnostics Inc operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma.